Growth/differentiation factor 3 (GDF3) is highly expressed in adipose tissue, and previous overexpression experiments in mice have suggested that it may act as an adipogenic factor under conditions of high lipid load. GDF3 has been shown to signal via the activin receptor ALK4 during embryogenesis, but functional receptors in adipose tissue are unknown. In this study, we show that Gdf3 ؊/؊ mutant mice accumulate less adipose tissue than WT animals and show partial resistance to high-fat diet-induced obesity despite similar food intake. We also demonstrate that GDF3 can signal via the ALK4-homolog ALK7 and the coreceptor Cripto, both of which are expressed in adipose tissue. In agreement with a role for ALK7 in GDF3 signaling in vivo, mutant mice lacking ALK7 also showed reduced fat accumulation and partial resistance to diet-induced obesity. We propose that GDF3 regulates adiposetissue homeostasis and energy balance under nutrient overload in part by signaling through the ALK7 receptor.
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high-fat diet ͉ metabolism ͉ TGF-␤ ͉ energy balance ͉ insulinemia L ong regarded as no more than an energy storage depot, adipose tissue has more recently emerged as an important regulator of metabolic homeostasis through the synthesis and release of peptide hormones by adipocytes, generally known as adipokines (1) . Because of the prominent role of adipose tissue in several human metabolic disorders, such as obesity and diabetes, the identification and characterization of adipokines is crucially important for our understanding of the role of adipose tissue as an integrator of homeostatic processes. Several members of the transforming growth factor-␤ (TGF-␤) superfamily of ligands-a structurally related but functionally heterogeneous group of cytokines that includes TGF-␤s, activins, bone morphogenetic proteins (BMPs) and growth/differentiation factors (GDFs)-are expressed in adipocytes, where they appear to have functions related to adipocyte differentiation. TGF-␤1 has been shown to block preadipocyte differentiation in vitro (2) , and transgenic overexpression of TGF-␤1 in mice led to lipodystrophy (3). The TGF-␤ protein myostatin, also known as GDF8, has been shown to regulate adipogenesis in vitro either directly or indirectly by blocking BMP signaling (4, 5) . In agreement with a role in adipocyte differentiation, targeted ablation of myostatin in mice reduced accumulation of adipose tissue and weight gain in mouse models of obesity (6) . It is, however, less clear whether TGF-␤ superfamily proteins can regulate mature adipocyte function in addition to differentiation.
Growth/differentiation factor 3 (GDF3, also called Vgr-2) is most prominently expressed in adult adipose tissue (7, 8) , and an earlier study found Gdf3 expression to be markedly increased in an obese-mouse model lacking adipocyte fatty acid-binding protein (FABP4/aP2) (9) . GDF3 overexpression in mice by adenovirus gene transfer resulted in increased adipose-tissue mass and weight gain under a high-fat diet but had no effect in a normal chow diet (10) , suggesting that GDF3 may act as an adipogenic factor under a high lipid load. However, whether endogenous GDF3 has any physiological function in adipose tissue and metabolic control has remained unknown. During embryogenesis, GDF3 has been shown to signal through a receptor complex comprising the activin type I receptor ALK4, type II receptors ActRIIA or B, and the coreceptor Cripto to control formation of anterior visceral endoderm and mesoderm (11, 12) . The receptors that mediate the functions of GDF3 in the adult have not been characterized.
We and others have recently shown that inactivation of the Gdf3 gene in mice leads to embryonic lethality in one-third of the mutant embryos because of pregastrulation developmental malformations (11, 12) . However, the majority of Gdf3 mutants survive until adulthood without any overt abnormality. In this study, we used these mice to investigate the requirement of GDF3 for adipose-tissue homeostasis under normal and high-fat diet regimes and elucidated a previously unknown receptor complex for GDF3 based on the type I receptor ALK7 that is likely involved in the effects of this cytokine in adult adipose tissue.
Results
Gdf3 ؊/؊ Mutant Mice Gain Less Weight During Diet-Induced Obesity Despite Normal Food Intake. The growth of WT and Gdf3 Ϫ/Ϫ mutant mice fed normal chow or a high-fat diet was monitored between 2 and 5 months of age. No significant differences were observed on chow (Fig. 1A) . In contrast, a significant difference in body weight was found after 5 weeks into a high-fat diet that persisted and increased over time (Fig. 1B) . After 14 weeks on a high-fat diet, the average weight increase for WT mice was 17.1 g but only 13.1 g for Gdf3 Ϫ/Ϫ mutants, a decrease in weight gain of 23% (Fig. 1B) . This difference was not due to reduced food intake, because WT and Gdf3 Ϫ/Ϫ mice consumed comparable amounts of food during this period (Fig. 1C) . The reduced weight gain of Gdf3 Ϫ/Ϫ mutants despite equal energy intake indicates that GDF3 is involved in the regulation of energy balance in mice.
Reduced Accumulation of Adipose Tissue in Mice Lacking GDF3. To determine whether the reduction in weight gain observed in Gdf3 Ϫ/Ϫ mice was due to a reduced accumulation of fat, we examined adipose tissues in WT and mutant mice after 14 weeks on chow or high-fat diets by using different approaches. The epididymal fat pads were significantly smaller in Gdf3 mutants under both the normal and high-fat diet regimes ( Fig. 2A) . In agreement with this observation, histological analysis of paraffin sections from epididymal fat pads revealed a marked decrease in adipocyte cell size in Gdf3 Ϫ/Ϫ mice compared with WT controls under both diet regimes (Fig. 2B ). Total body fat was then investigated by using MRI, which revealed reductions in both visceral and subcutaneous fat depots in the mutants (Fig. 2C) . Quantification of total body fat from MRI scans showed that Gdf3 Ϫ/Ϫ mice had on average 44% and 28% less body fat than WT controls after 14 weeks on chow and high-fat diet, respectively ( Fig. 2D) . At the end of 14 weeks on the high-fat diet, the mutants accumulated 2.5 g less of fat than WT controls, which accounts for Ϸ60% of their reduction in body weight.
Expression and Functional Characterization of a GDF3 Receptor Complex Based on the Type I Receptor ALK7. GDF3 has been shown to directly bind and signal through a receptor complex consisting of a type I receptor (the activin receptor ALK4), a type II receptor (either ActRIIA or -B), and the GPI-anchored coreceptor Cripto (11, 12) . The dependence of GDF3 signaling on the presence of Cripto resembles the signaling mechanism used by two other TGF-␤ superfamily ligands, namely Nodal and GDF1 (13) (14) (15) . Because both Nodal and GDF1 have also been shown to signal via the related type I receptor ALK7 (13, 16) , we speculated that GDF3 may also be able to signal via ALK7 in the presence of Cripto. We first investigated the expression of candidate receptor components in adipose tissue by RT-PCR using RNA isolated from visceral fat of WT, Gdf3 Ϫ/Ϫ , and Alk7 Ϫ/Ϫ mice. This analysis confirmed expression of Gdf3, Alk7, Alk4, ActRII-A, ActRII-B, and Cripto in adipose tissue from WT animals (Fig. 3A) . We then investigated whether GDF3 may signal through a receptor complex including ALK7 by transient transfection in heterologous cells by using a gene reporter construct based on a promoter element (CAGA-luc) that reports activation of Smad3, a key downstream mediator of TGF-␤ superfamily signaling (17) . R4-2 cells express low levels of type I receptors, but normal levels of type II receptors, and are therefore well suited for functional analysis of exogenous type I receptor molecules. In the presence of both ALK7 and Cripto, GDF3 could robustly activate the CAGA-luc reporter in R4-2 cells (Fig. 3B) . A second assay was performed in HepG2 cells by using an ALK7 chimeric receptor (ALK7/3) carrying the intracellular L45 loop from the BMP receptor ALK3, which allows it to activate a reporter construct carrying a BMP-responsive element (BRE-luc) (18) (19) (20) . As expected, GDF3 had no effect on its own in this assay, whereas BMP4 could readily activate the reporter in the absence of any additional component (Fig. 3C ). However, GDF3 was able to robustly activate the reporter in the presence of the ALK7/3 chimera and Cripto (Fig. 3C) . The ability of ALK7 to mediate GDF3 signaling, together with its expression in adipose tissue along with type II receptors and Cripto, suggested that ALK7 may participate in the effects of GDF3 on energy balance and fat accumulation and prompted us to investigate whether mice lacking ALK7 display any of the phenotypes found in Gdf3 Ϫ/Ϫ mutants. in weight gain was observed after 10 weeks into a high-fat diet (Fig.  4A ). After 14 weeks on the high-fat diet, the average weight increase for WT mice was 17.2 g but only 12.2 g for Alk7 Ϫ/Ϫ mutants, a decrease in weight gain of 29% (Fig. 4A) . As in Gdf3 Ϫ/Ϫ mutants, food intake was also comparable between mice lacking ALK7 and WT controls (Fig. 4B) , suggesting abnormal energy balance in the mutants. A strong reduction in the size of epididymal fat pads was also observed in Alk7 Ϫ/Ϫ mutants after a high-fat diet but not after a normal chow diet (Fig. 4C) . Moreover, adipocytes in epididymal fat pads of mice lacking ALK7 were also smaller in size (Fig. 4D) . Quantification of total body fat by MRI revealed a reduction of 25% in body fat content in Alk7 Ϫ/Ϫ mutants after a high-fat diet (Fig. 4 E and F) . No difference was found in mice fed a normal chow diet (data not shown). These data indicate that, on a high-fat diet, Alk7 Ϫ/Ϫ mutants phenocopy the weight gain and fat-accumulation abnormalities observed in mice lacking GDF3 but appear to be less affected when fed a normal chow diet.
Mice Lacking GDF3, Unlike Those Lacking ALK7, Display Normal
Insulinemia and Insulin Sensitivity. We have recently shown in a separate study that ALK7 functions as a negative regulator of insulin secretion in pancreatic islets and that mice lacking ALK7 have elevated serum insulin levels from early postnatal stages and develop reduced insulin sensitivity and liver steatosis as adults (21) . It was therefore of interest to determine whether mice lacking GDF3 display similar abnormalities. Unlike Alk7 Ϫ/Ϫ mice, however, Gdf3 Ϫ/Ϫ mutants showed normal serum insulin levels (Fig. 5A) and insulin sensitivity (Fig. 5B) . Moreover, the liver weight of mice lacking GDF3 was similar to that of WT controls after both regular chow or high-fat diet (Fig. 5C ). Unlike the livers of Alk7 Ϫ/Ϫ mutants, Gdf3 Ϫ/Ϫ livers showed no signs of elevated lipid accumulation in a normal chow diet as assessed by Oil red-O staining (Fig. 5D) . These data suggest a more restricted role of GDF3 in the control of weight gain and buildup of adipose tissue than its receptor ALK7.
Discussion
The results of this study support a role for GDF3 as an important endogenous regulator of fat accumulation and energy balance. We also show that GDF3 is able to signal via a receptor complex based on ALK7 and Cripto, both of which are endogenously expressed in adipose tissue. In agreement with a role for ALK7 in GDF3 signaling in vivo, mice lacking this receptor show similar abnormalities in diet-induced fat accumulation and weight gain to those observed in Gdf3 Ϫ/Ϫ mutants. Alk7 Ϫ/Ϫ mice, however, display a wider range of defects than Gdf3 Ϫ/Ϫ mutants, particularly with regard to serum insulin levels and insulin sensitivity, suggesting the involvement of other ALK7 ligands in those functions. In agreement with this, we have recently found that activin B signals through ALK7 to negatively regulate Ca 2ϩ influx in pancreatic ␤-cells and that mice lacking activin B (Inh␤B Ϫ/Ϫ mice) show hyperinsulinemia comparable with that of Alk7 Ϫ/Ϫ mutants (21) . Double mutants lacking both activin B and ALK7 showed no additive effects, suggesting that they function in a common pathway to regulate serum insulin levels. Thus, the more complex phenotype displayed by Alk7 Ϫ/Ϫ mice may result from defects in the signaling activities of several ligands of this receptor. Interestingly, in contrast to Alk7 Ϫ/Ϫ mice, neither Gdf3 Ϫ/Ϫ or Inh␤B Ϫ/Ϫ mutants show signs of reduced insulin sensitivity or liver steatosis (this study and ref. 21 ). Those phenotypes could thus be the result of defects in the activities of yet additional ALK7 ligands or, perhaps more interestingly, arise as a synergistic effect of combined hyperinsulinemia and reduced fat deposition caused by abnormalities in both activin B and GDF3 signaling. This possibility could be addressed in future studies by the generation and analysis of compound Gdf3 Ϫ/Ϫ ;Inh␤B Ϫ/Ϫ double mutants. It should, however, be noted that, because of the ability of GDF3 and activin B to activate ALK4 as well as ALK7, the genetics of a signaling network with ligands that have several receptors and receptors that have multiple ligands can be complicated, and it is unlikely that compound mutations in either ligands or receptors will strictly phenocopy each other.
In a previous study, intravenous injection of an adenoviral vector driving GDF3 overexpression increased fat accumulation and weight gain in mice undergoing a high-fat diet but had no effect in animals fed normal chow, leading the authors of that study to propose that GDF3 actions may be restricted to conditions of nutrient overload (10) . However, our observation that mice lacking GDF3 have less adipose tissue than WT controls even when fed regular chow indicates that GDF3 has a more general role in fat accumulation independently of the regime of energy intake. In contrast to Gdf3 Ϫ/Ϫ mutants, Alk7 Ϫ/Ϫ mice appeared to be less affected when fed a chow diet, suggesting that perhaps ALK4 may compensate for the lack of ALK7 under those conditions. Alk4 Ϫ/Ϫ mutants die early in embryonic development (22) and are therefore unsuitable to assess the adult roles of this receptor. Intriguingly, one study has reported increased Alk7 expression in cell lines after exposure to fatty acids (23) , which would be in agreement with a more prominent role for ALK7 during nutrient overload.
The coexpression of GDF3 and its receptors in adipose tissue suggests that at least part of the effects of this ligand on fat cells are mediated in a paracrine fashion. Although adipose tissue is the most prominent site of GDF3 expression, this ligand has also been detected in circulation in the bloodstream (9) and may thus affect fat deposition and energy balance through non-cell-autonomous effects. The requirement for the Cripto coreceptor, which is excluded from several tissues that express other GDF3 receptor components-such as pancreatic ␤-cells (24) , is likely to provide tissue specificity to GDF3 signaling. Future studies, including conditional inactivation, will be required to unravel tissue-specific effects of GDF3 and its receptors. From a therapeutic point of view, our results suggest that GDF3 antagonists or inhibitors may find clinical applications in the control of diet-induced obesity and fat deposition, particularly in individuals exposed to diet regimes of high caloric intake.
Materials and Methods
Animal Studies. The mutant mice used in this study have been described in detail (11, 25) . Both Gdf3 and Alk7 mutant mice were maintained in an Sv129OlaHsd inbred background. Approximately one-third of Gdf3 mutant mice displayed lethal patterning and differentiation alterations during early embryogenesis, although the majority of Gdf3 mutants survive because of redundancy of Nodal and Gdf1 (11, 12) . Mice were genotyped by PCR as described (11, 25) . Animals were housed under standard conditions in a pathogen-free environment with food and water ad libitum. High-fat diet (D12492; Research Diets) was given to 7-to 8-week-old mice for 14 weeks before subsequent tissue analyses. The composition of the high-fat diet was (in kcal%) 60% fat, 20% carbohydrate, and 20% protein. Animal protocols were approved by Stockholms Norra Djurfö rsö ksetiska Nä mnd and were in accordance with ethical guidelines of the Karolinska Institute.
Receptor Reconstitution Experiments. Receptor reconstitution and reporter gene experiments were performed in R4-2 and HepG2 cells cultured in 24-well plates, as described (13) . The mature domain of GDF3 was expressed from a chimeric construct carrying a prodomain from activin B to enhance signaling strength, as described (11) . The chimeric type I receptor ALK7 L45-ALK3 (ALK7/3) was generated by substituting Asn-257, Asp-259, Asn-260, and Thr-262 of ALK7 with Ile-269, Gly-271, Thr-272, and Ser-274 by site-directed mutagenesis. The amounts of plasmid DNA transfected into cells (per three wells) were as follows: 10 ng for WT ALK7, 100 ng for chimeric ALK7/3, 30 ng for Cripto, and 800 ng for GDF3.
Histological Analysis. Freshly dissected tissues were fixed in formalin before paraffin embedding and sectioning. H&E staining of sections was performed according to standard procedures. Oil red-O (Sigma-Aldrich) staining was performed on frozen liver sections by following standard protocols.
MRI Scans and Analysis. In vivo MRI measurements were made under 1.5-2% isoflurane in O2 anesthesia. Fat distribution was measured in every mouse after 14 weeks on either chow or high-fat diet. All in vivo magnetic resonance (MR) measurements were performed on a Bruker 4.7-T field-strength magnet and a 40-cm horizontal bore diameter (Bruker Biospec Avance 47/40; Bruker) equipped with a commercially available circular resonator (Bruker) with an inner diameter of 24 mm for RF pulse application and signal detection. Body temperature was maintained by using a temperature-controlled air stream around the body of the mouse. For the measurement of whole-body adiposity, the main sequence used was a Bruker implementation of rapid acquisition with relaxation enhancement (RARE) imaging (26) as described (27) . Briefly, the mouse was laid on a support and positioned in the center of the coil. A total of 40 contiguous 1.5-mm-thick transversal slices covering the mouse body were recorded. Image analysis was carried out with Paravision 2.3 image analysis software (Bruker). MRI-visible visceral fat comprises omental, retroperitoneal, and mesenteric fat depots. Two-dimensional image series were then imported into Biomap platform (IDL) for pixel counting-based determination of fat volumes. A signal threshold was used after applying a G filter, a maximum likelihood, and a class-select interaction to exclude all nonfat tissues in each slice. A density factor of 0.9 g/ml was used to convert fat volumes (in milliliters) into fat mass (in grams).
RT-PCR Analysis. Total RNA extraction from freshly dissected tissues was performed by TRIzol (Invitrogen) according to the manufacturer's instructions. PCR was performed by using 1 g of reverse-transcribed cDNA (SuperScript II RT-kit; Invitrogen) and primers for Alk7, Alk4, Gdf3, ActRII-A, ActRII-B, Cripto, and Gapdh (primers sequences available upon request).
Metabolic Measurements. Serum insulin levels were measured in animals fasted overnight by using a mouse ELISA kit (Mercodia). Insulin tolerance tests were performed with mice starved for 3 h. Briefly, animals were given 1 unit/kg of body weight of recombinant human insulin (Actrapid; Novo Nordisk) by i.p. injection. Glucose levels were measured by tail-tip bleeding by using a FreeStyle mini Glucometer (Abbott) immediately before and 15, 30, 60, and 90 min after the insulin injection.
Statistical Analysis. Each variable was analyzed by using the unpaired Student's t test unless otherwise indicated. For all analyses, a P value of Ͻ0.05 was considered significant. Results are given as means Ϯ SEM. All analyses were performed by using Prism4 Software (GraphPad).
